Stein D S, Verano A S, Levandowski R A
Department of Medicine, University of Illinois, College of Medicine, Chicago.
Am J Gastroenterol. 1988 Jun;83(6):684-6.
Disseminated cytomegalovirus (CMV) infection in a liver transplant recipient was treated successfully by administration of ganciclovir (BW B759U) at a dosage of 7.5 mg/kg/day for 2 wk in the face of continuation of chemical immunosuppression. The spectrum of illness included symptomatic esophagitis and hepatic dysfunction associated with the appearance of CMV inclusion bodies, retinal lesions, and bone marrow suppression. Clinical improvement during therapy with ganciclovir was prompt and was paralleled by reversal of histological abnormalities. CMV was recovered from none of the cultured tissues after the start of therapy. Ten months after discontinuation of ganciclovir, the patient had no evidence of further CMV disease. The observation suggests that replicative CMV infection in organ-transplanted patients may be suppressed by relatively low dose ganciclovir, even when the patients are maintained on immunosuppressive regimens designed to prevent graft rejection.
一名肝移植受者发生播散性巨细胞病毒(CMV)感染,在持续进行化学免疫抑制的情况下,给予剂量为7.5mg/kg/天的更昔洛韦(BW B759U)治疗2周,成功治愈。疾病谱包括有症状的食管炎、与CMV包涵体出现相关的肝功能障碍、视网膜病变和骨髓抑制。更昔洛韦治疗期间临床迅速改善,组织学异常也随之逆转。治疗开始后,所有培养组织均未分离出CMV。停用更昔洛韦10个月后,患者没有进一步CMV疾病的迹象。该观察结果表明,即使器官移植患者维持旨在预防移植排斥的免疫抑制方案,相对低剂量的更昔洛韦也可能抑制其复制性CMV感染。